GSK, mRNA
Experimental mRNA cancer vaccine shows potential for advanced stage cancer patients in Phase 1 trial
Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers. The investigational mRNA cancer immunotherapy is targeted for patients with lung cancer,
Moderna Inc (MRNA) stock saw a decline, ending the day at $69.86 which represents a decrease of $-2.13 or -2.96% from the prior close of $71.99. The stock opened at $72.19 and touched a low of $69.82 ...
A German study published in July 2024 did not find that mRNA COVID-19 vaccines damaged children’s immune systems, contrary to ...
Even as the Covid wave in Florida continues, Gov. Ron DeSantis’ administration is once again advising against the mRNA ...
Florida health officials are raising alarms about the safety of the newest versions of mRNA COVID-19 vaccines, advising ...
RBC Capital analyst Luca Issi maintained a Hold rating on Moderna (MRNA – Research Report) today and set a price target of $75.00. The ...
Frustrated when Brazil could not get COVID vaccines, two Brazilian doctors (who have been best friends since college) decided ...
Based on the high rate of global immunity and currently available data, the State Surgeon General advises against the use..." ...
New York, New York-- (Newsfile Corp. - September 18, 2024) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Moderna, Inc. (NASDAQ: MRNA) between January 18 ...
Primrose Bio, a San Diego biotech company, has begun a partnership to jointly develop and market products for mRNA medicines.
GlobalData on MSN6d
ESMO 2024: Moderna’s mRNA solid tumour vaccine shows early promiseModerna's mRNA-4359 has shown early signs of efficacy, activating key proteins to trigger an immune response for cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback